Haemonetics Corporation
HAE
$71.65
$1.191.69%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.36B | 1.37B | 1.36B | 1.33B | 1.31B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.36B | 1.37B | 1.36B | 1.33B | 1.31B |
| Cost of Revenue | 586.02M | 608.93M | 611.62M | 604.92M | 597.14M |
| Gross Profit | 774.81M | 764.59M | 749.61M | 728.97M | 711.92M |
| SG&A Expenses | 418.73M | 417.16M | 417.53M | 420.87M | 422.99M |
| Depreciation & Amortization | 48.26M | 47.39M | 42.07M | 37.03M | 32.03M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.11B | 1.13B | 1.13B | 1.12B | 1.10B |
| Operating Income | 246.70M | 239.23M | 232.11M | 217.05M | 204.66M |
| Income Before Tax | 212.07M | 164.75M | 158.86M | 146.99M | 151.87M |
| Income Tax Expenses | 44.39M | 34.68M | 35.05M | 32.10M | 34.31M |
| Earnings from Continuing Operations | 167.68 | 130.07 | 123.81 | 114.89 | 117.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 167.68M | 130.07M | 123.81M | 114.89M | 117.56M |
| EBIT | 246.70M | 239.23M | 232.11M | 217.05M | 204.66M |
| EBITDA | 355.58M | 345.65M | 333.04M | 311.91M | 293.28M |
| EPS Basic | 3.34 | 2.56 | 2.43 | 2.26 | 2.32 |
| Normalized Basic EPS | 2.78 | 2.75 | 2.75 | 2.62 | 2.36 |
| EPS Diluted | 3.32 | 2.54 | 2.41 | 2.23 | 2.29 |
| Normalized Diluted EPS | 2.76 | 2.73 | 2.72 | 2.59 | 2.33 |
| Average Basic Shares Outstanding | 201.32M | 202.91M | 203.40M | 203.23M | 202.82M |
| Average Diluted Shares Outstanding | 202.92M | 204.85M | 205.66M | 205.81M | 205.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |